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Abstract: Plasmodium vivax shows a strict host tropism for reticulocytes. We identify 
transferrin receptor 1 (TfR1) as the receptor for P. vivax reticulocyte-binding protein 2b 
(PvRBP2b). The structure of the N-terminal domain of PvRBP2b involved in red blood cell 
binding was determined, elucidating the molecular basis for TfR1 recognition. TfR1 was 
validated as the biological target of PvRBP2b engagement by TfR1 expression knockdown 
analysis. TfR1 mutant cells deficient in PvRBP2b binding were refractory to invasion of P. 
vivax, but not to invasion of P. falciparum. Using Brazilian and Thai clinical isolates, we show 
that PvRBP2b monoclonal antibodies that inhibit reticulocyte binding also block P. vivax entry 
into reticulocytes. These data show that TfR1-PvRBP2b invasion pathway is critical for the 
recognition of reticulocytes during P. vivax invasion.  
One Sentence Summary: Invasion of immature red blood cells by the malaria parasite, 
Plasmodium vivax, is mediated by binding to the host’s transferrin receptor. 
 
 
 
 
 
 
 
 
 
Main Text:  
 Of the hundreds of Plasmodium species, only P. falciparum, P. vivax, P. ovale curtisi, P. 
ovale wallikeri, P. malariae and P. knowlesi are known to infect humans. Within the human host, 
malaria parasites invade liver and red blood cells for replication and transmission. Blood stage 
infection is the major cause of all clinical symptoms in malaria, and therefore the therapeutic 
prevention of parasite entry into red blood cells could alleviate malarial disease. Entry into red 
blood cells depends on the interactions between parasite invasion ligands and their cognate red 
blood cell receptors of which only a handful have been identified (1–7). These ligand-receptor 
interactions initiate a cascade of molecular events that progress from initial attachment, 
recognition, commitment and finally penetration of the parasite into red blood cells (8, 9). 
 P. vivax is the most widely distributed human malaria parasite. This parasite has a strict 
preference for invasion into reticulocytes, which are very young red blood cells that are formed 
in the bone marrow following enucleation and released into the circulation. The reticulocyte-
specific receptor involved in P. vivax entry has not been identified (10). Most studies have 
focused on the interaction between the P. vivax Duffy binding protein (PvDBP) and the red 
blood cell Duffy antigen receptor for chemokines (DARC) as individuals from western and 
central Africa lacking DARC are resistant to P. vivax invasion (11). However, recent reports 
have highlighted the presence of P. vivax in apparently DARC negative individuals suggesting 
that P. vivax may enter reticulocytes by binding to other receptors (12–14). Furthermore, DARC 
is present on both normocytes and reticulocytes and therefore this ligand-receptor interaction 
cannot govern selective entry into reticulocytes (15). To identify other parasite proteins involved 
in reticulocyte recognition, we focused on the P. vivax reticulocyte-binding protein family 
(PvRBP). This protein family comprises 11 members of which several have been shown to bind 
reticulocytes; however, their cognate receptors have not been identified (16–19). 
PvRBP2b binds transferrin receptor 1 to mediate recognition of reticulocytes 
P. vivax preferentially invades reticulocytes expressing high levels of transferrin receptor 
1 (TfR1 or CD71) (20). TfR1 is an essential housekeeping protein involved in cellular transport 
of iron into cells through binding of iron-loaded transferrin (Tf) (21). On circulating red blood 
cells, TfR1 is expressed only on reticulocytes and is progressively lost from their membranes as 
they mature into erythrocytes (22, 23). TfR1 is a type II transmembrane glycoprotein that forms 
a dimer and its ectodomain consists of three subdomains: a ‘protease-like domain’ resembling 
the structure of zinc metalloproteinases, an ‘apical domain’ and a ‘helical domain’ responsible 
for dimerization (24). TfR1 is also a cellular receptor for New World hemorrhagic fever 
arenaviruses including Machupo (MACV), Junin, Guanarito and Sabiá viruses (25, 26). Residues 
208-212 of the TfR1 apical domain provide a critical recognition site for these viruses (25, 26). 
PvRBP2b is expressed in late-stage P. vivax parasites and recombinant PvRBP2b 
(residues 161 to 1,454, PvRBP2b161-1454) binds preferentially to reticulocytes that express TfR1 
(19, 27). We observed that binding by recombinant PvRBP2b was abolished when reticulocytes 
were treated with trypsin and chymotrypsin (fig. S1, A and B). We confirmed that the 
combination of these proteases cleaves TfR1 and CR1 from the surface of reticulocytes, with 
other known malaria receptors including glycophorin A, basigin and DARC being susceptible to 
different sets of protease treatment (fig. S1, A and B). The profile of PvRBP2b binding is 
strikingly similar to the TfR1 surface expression on reticulocytes (Fig. 1A, bottom panel) and we 
show that the level of PvRBP2b binding is directly correlated with the levels of TfR1 on the 
surface of reticulocytes (fig. S1, C and D).  
To determine if PvRBP2b161-1454 binds to the population of reticulocytes that express 
TfR1 on their surfaces, we tested a panel of commercially available anti-TfR1 monoclonal 
antibodies (mAbs) for their ability to block recombinant PvRBP2b binding. Indeed, anti-TfR1 
mAbs 23D10, L01.1, LT71, M-A712, MEM-189 and OKT9 inhibited PvRBP2b binding to 
reticulocytes by 78, 76, 33, 75, 92 and 90% respectively (Fig. 1A). M-A712 also prevents 
MACV pseudovirus entry (25, 28). Anti-TfR1 mAbs 2B6, 13E4 and MEM-75 did not inhibit 
PvRBP2b binding; while their epitopes have not been mapped, we propose that these three 
antibodies may bind to a site on TfR1 that is not involved in the PvRBP2b interaction (Fig. 1A). 
To determine if this inhibition was specific to PvRBP2b161-1454 binding, we analyzed the binding 
of P. falciparum reticulocyte binding protein-like homologue 4 (PfRh4) to its cognate receptor 
complement receptor 1 (CR1) (4). While addition of the first three complement control protein 
modules of CR1 (CCP 1–3) inhibited PfRh428-766 binding as expected (29), addition of anti-TfR1 
mAb OKT9 did not significantly reduce PfRh4 binding (Fig. 1B). Since anti-TfR1 did not affect 
PfRh4 binding, these results show that TfR1 is a specific reticulocyte receptor for PvRBP2b. 
To evaluate if PvRBP2b161-1454 interacts directly with TfR1, we performed immuno-
precipitation experiments using purified recombinant TfR1, Tf, and PvRBP2b161-1454 proteins 
(Fig. 1C) (30). Using an anti-PvRBP2b mAb, we immuno-precipitated PvRBP2b in complex 
with TfR1 and Tf. PvRBP2b and TfR1 also formed a binary complex in the absence of Tf, 
demonstrating that PvRBP2b binds directly to TfR1 (Fig. 1C). The interaction between 
PvRBP2b and TfR1 is specific, as immuno-precipitation of PvRBP1a, PvRBP1b or PvRBP2a 
did not show evidence of complex formation with TfR1 (fig. S2A).  
We developed a fluorescence resonance energy transfer (FRET)-based assay to monitor 
PvRBP2b-TfR1 complex formation where TfR1 labeled with DyLight-594 could be shown to 
interact with PvRBP2b161-1454 labeled with DyLight-488 (fig. S2B). The addition of 10-fold 
molar excess of unlabeled PvRBP2b161-1454 and TfR1 competed out the labeled proteins and 
reduced the signal of the PvRBP2b-TfR1 FRET pair. In contrast, proteins that were unable to 
bind TfR1, such as PfRh4, had no effect on the FRET signal. Using this assay, we observed that 
anti-TfR1 mAbs 23D10, M-A712, MEM-189 and OKT9 that inhibited PvRBP2b161-1454 
reticulocyte binding also blocked PvRBP2b-TfR1 complex formation (Fig. 1D). 
MACV GP1 and PvRBP2b bind to the apical domain of TfR1 
The arenavirus envelope glycoprotein is the only protein on the virion surface and during 
maturation is processed into three subunits: the stable signal peptide (SSP), GP1 and GP2. The 
GP1 subunit interacts with cellular receptors and the structure of a MACV GP1-TfR1 complex 
shows that MACV GP1 binds to the apical domain of TfR1 (31, 32). To determine if PvRBP2b 
interacts with a similar surface on TfR1, we examined if soluble MACV GP1 competes with 
PvRBP2b161-1454 for binding to TfR1 on reticulocytes (Fig. 1E). Indeed, the addition of MACV 
GP1 reduced PvRBP2b161-1454 binding to reticulocytes, albeit at a lower level of inhibition 
compared to the addition of anti-TfR1 mAb MEM-189. This inhibition was specific as PfRh4 
binding was unaffected by addition of MACV GP1 or MEM-189, but clearly reduced with the 
addition of CCP 1-3 (Fig. 1E). The addition of MACV GP1 inhibited PvRBP2b-TfR1 complex 
formation and reduced the FRET signal to a similar extent as unlabeled PvRBP2b161-1454 whereas 
addition of CCP 1-3 had negligible effect (Fig. 1F). These results indicate that MACV GP1 and 
PvRBP2b161-1454 bind to an overlapping site on TfR1. 
Crystal structure of the N-terminal domain of PvRBP2b 
 PvRBP2b is a 326 kDa protein with a putative red blood cell binding domain and a C-
terminal transmembrane region (Fig. 2). We determined the crystal structure of the N-terminal 
domain of PvRBP2b (residues 169 to 470, PvRBP2b169-470), refined to 1.71 Å resolution (Fig. 
2A, fig. S3, A to D, and table S1). The surface of the domain is mostly positively charged (Fig. 
2B). It is predominantly an α-helical protein, comprising ten α-helices and two very short 
antiparallel β-sheets, each comprising of two β-strands. The crystal structure of PvRBP2b169-470 
has two disulfide bonds; one between Cys312 and Cys316 and the other between Cys240 and 
Cys284. This structure closely resembles the homologous domain of PvRBP2a and PfRh5, with 
a root mean square deviation (RMSD) of 1.7 Å and 3.7 Å over 268 and 225 aligned Cα atoms, 
respectively (Fig. 2C and fig. S4) (18, 33, 34). The theoretical X-ray solution scattering pattern 
calculated from the PvRBP2b169-470 crystal structure coordinates shows excellent agreement with 
the experimental small angle X-ray scattering (SAXS) data (χ = 0.35; fig. S5, A to F, and table 
S2), with concordance between the crystal and solution conformations apparent from the overlay 
of the crystal structure and the ab initio calculated molecular envelope (Fig. 2D, left). We also 
obtained SAXS data for a longer fragment of PvRBP2b including residues 169 to 652 (fig. S6 
and table S2). The reconstructed molecular envelope has a rod-like shape with a C-terminal part 
forming a continuous extension of the N-terminal domain (Fig. 2D, right). SAXS data for a 
larger fragment of PvRBP2b encompassing residues 161 to 969 indicate that the molecule adopts 
an elongated, boomerang-like shape, similar to that previously reported for PvRBP2a (fig. S6, A 
to F, fig. S7, A to D, and table S2) (18). 
We calculated nucleotide diversity (π) and Tajima’s D within PvRBP2b using data from 
the MalariaGEN P. vivax Genome Variation project (35). There was a peak in both metrics 
between amino acid positions 169 and 470, suggesting balancing selection within the N-terminal 
domain (Fig. 2E). Such signatures of balancing selection are often associated with genes or 
proteins expressed on the surface of merozoites, and are likely due to interaction with the 
immune system. 
To determine the importance of the N-terminal domain for PvRBP2b function, we 
generated a series of purified recombinant PvRBP2b protein fragments (Fig. 2F, tables S3 and 
S4). All proteins were soluble and properly folded as indicated by high α-helical content in CD 
spectra, in agreement with the secondary structure predictions (fig. S8, A to D). We observed 
that all fragments with the N-terminal domain bound reticulocytes (PvRBP2b161-1454, 
PvRBP2b161-969, PvRBP2b169-813 and PvRBP2b169-652) whereas their corresponding fragments 
without the domain did not (PvRBP2b474-1454 and PvRBP2b474-969) (Fig. 2G). However, the 
isolated N-terminal domain PvRBP2b169-470 was unable to bind reticulocytes on its own (Fig. 
2G), indicating that this fragment of PvRBP2b is necessary but not sufficient for reticulocyte 
binding. The shortest PvRBP2b fragment that showed binding to reticulocytes encompasses 
residues 169 to 652 (Fig. 2G). Our FRET-based assay showed that unlabeled recombinant 
fragments that bind reticulocytes inhibited PvRBP2b-TfR1 complex formation whereas 
recombinant fragments that did not bind reticulocytes had a negligible effect (Fig. 2H). 
Collectively our structural and functional analyses indicate that the N-terminal domain is 
necessary for binding, but requires the presence of the elongated C-terminal fragment to form a 
fully functional binding site. 
PvRBP2b, TfR1 and Tf form a stable complex at nanomolar concentrations 
Using surface plasmon resonance (SPR), we found that PvRBP2b161-1454 interacts with 
TfR1 alone or with the binary complex of TfR1-Tf (Fig. 3A, top and bottom panels, 
respectively). We also observed similar results for the PvRBP2b161-969 fragment with TfR1 and 
TfR1-Tf (Fig. 3B, top and bottom panels, respectively). These results indicate that Tf was not 
required for the PvRBP2b-TfR1 complex formation, since the addition of Tf resulted in similar 
binding responses than for TfR1 alone. We analyzed a PvRBP2b, TfR1 and Tf ternary complex 
using analytical size exclusion chromatography (SEC), and used SDS-PAGE analyses to confirm 
co-migration of complex components. The ternary complex was detected for PvRBP2b161-1454 
and PvRBP2b161-969 (Fig. 3, C and D, top panels respectively, and table S5). In contrast, their 
corresponding fragments without the N-terminal domain (PvRBP2b474-1454 and PvRBP2b474-969) 
did not form any observable ternary complexes (Fig. 3, C and D, bottom panels). The interaction 
between PvRBP2b and TfR1-Tf binary complex is similar in the presence of either the iron-
depleted or iron-loaded form of human transferrin (fig. S2C). Furthermore, the homologous 
member of the same protein family, PvRBP2a, did not form a ternary complex with TfR1-Tf 
(fig. S2D).  
Sedimentation velocity analyses of TfR1, Tf and PvRBP2b161-969 indicated that the 
isolated proteins are homogenous, with weight-average sedimentation coefficients of 7.3 S, 4.9 S 
and 3.6 S, respectively (Fig. 3E). These values are consistent with a stable dimer of TfR1 and 
monomeric forms of both Tf and PvRBP2b161-969. The empirically-fitted shape parameter value 
(frictional ratio) calculated for PvRBP2b161-969 was approximately 1.8, consistent with a highly 
elongated structure in solution. Mixtures of TfR1-Tf and PvRBP2b161-969-TfR1-Tf yielded single 
symmetrical peaks with weight-average sedimentation coefficients of 11.5 S and 11.2 S, 
respectively, with no peaks observed for the individual components in these samples (Fig. 3F and 
fig. S9). These results indicate that Tf and TfR1 form a stable binary complex in solution and 
that PvRBP2b161-969 binds to this binary complex. The frictional ratio (f/f0) for the ternary 
PvRBP2b161-969-TfR1-Tf was higher than for the binary TfR1-Tf complex, resulting in a 
reduction in the sedimentation coefficient on formation of the ternary complex and indicating 
that it has an elongated structure in solution. 
Deletions in TfR1 generated via CRISPR/Cas9 abolishes PvRBP2b binding and P. vivax 
invasion 
To investigate whether loss of TfR1 surface expression on red blood cells would affect 
PvRBP2b protein binding, we attempted to generate a knockout of the TFRC gene using 
CRISPR/Cas9 genome editing of the JK-1 erythroleukemia cell line. We obtained single cell 
clones that displayed reduced expression of TfR1 and validated the mutation in two independent 
clones (TfR1 mut1 and TfR1 mut2) (fig. S10, A to C). Both clones contained an identical -3 bp 
deletion that resulted in the loss of amino acid Gly217 in the TfR1 apical domain, but left the rest 
of the protein in-frame. TfR1 mut1 was homozygous for this deletion while TfR1 mut2 has a -3 
bp as described above on one allele and a -11 bp deletion on the other allele, the latter leading to 
a premature stop codon. Deletion of TFRC in a mouse model is embryonic lethal and leads to 
severe disruption of erythropoiesis (36), suggesting that complete deletion of TFRC in erythroid-
lineage cells, such as JK-1 may not be possible.  
Differentiated polychromatic JK-1 cells (termed jkRBCs) express surface proteins 
(including TfR1) at levels comparable to differentiated CD34+ bone marrow-derived cultured 
red blood cells (cRBCs) (37). The jkRBCs, cRBCs and differentiated jkRBCs with a knockout 
within the basigin receptor (∆BSG) show normal levels of TfR1 whereas TfR1 mutant clones 
displayed an intermediate level of TfR1 surface staining with a panel of anti-TfR1 mAbs (Fig. 
4A and fig. S11). Levels of glycophorin A (GypA) and basigin (BSG) on these TfR1 mutant 
clones were similar to all control cells, showing that only TfR1 surface expression is affected on 
these cells (Fig. 4A). To determine if deletion of Gly217 affects PvRBP2b binding, we generated 
a recombinant TfR1 protein lacking this amino acid (TfR1∆G217). Using SEC, we show that 
while TfR1∆G217 was still able to bind Tf, its binding to PvRBP2b was completely abolished 
(Fig. 4B). Gly217, which resides on the lateral surface of the TfR1 apical domain is close to the 
MACV GP1 interaction surface (fig. S10D) (31). 
To confirm that the mutation in TFRC did not result in changes in expression of other red 
blood cells proteins, we compared the abundance of cell surface proteins between wildtype 
jkRBCs and the two TfR1 mutants using tandem mass tag-based quantitative surface proteomics 
(Fig. 4C). Out of 237 quantified surface proteins, only TfR1 and Tf were significantly modified, 
confirming the specificity of the TFRC mutations. 
We next wanted to determine if PvRBP2b binding was affected in the TfR1 mutant 
clones. PvRBP2b161-1454 and PvRBP2b161-969 bound jkRBCs and cRBCs, whereas recombinant 
fragments PvRBP2b474-1454 and PvRBP2b474-969 that lacked the N-terminal domain did not (Fig. 
4D). In contrast, we did not detect any PvRBP2b161-1454 and PvRBP2b161-969 binding to TfR1 
mutant cells. This abolition of binding was specific to deletions in TFRC as PvRBP2b binding 
was unaffected on ∆BSG null cells or on cRBCs (Fig. 4D, right panel). We also compared the 
invasion efficiency between jkRBCs and TfR1 mutant cell lines with either Brazilian P. vivax 
isolates or P. falciparum 3D7 (Fig. S10E). A significant (> 10-fold) reduction in invasion 
efficiency was observed in the TfR1 mutant line compared to the jkRBCs line with P. vivax, 
while no significant difference was observed with P. falciparum (Fig. 4E). These results validate 
TfR1 as the cognate receptor for PvRBP2b and that TfR1 is an essential host factor for P. vivax 
invasion. 
Anti-PvRBP2b antibodies block reticulocyte-binding and P. vivax invasion 
To examine if PvRBP2b antibodies could inhibit P. vivax invasion, we raised mouse 
monoclonal antibodies to PvRBP2b161-1454 and obtained four mAbs. 3E9, 6H1 and 10B12 bound 
epitopes within the N-terminal domain present in PvRBP2b169-470 with high affinities (Fig. 5A, 
fig. S12, A to C, and table S6), while mAb 8G7 recognized an epitope outside the N-terminal 
domain within amino acids 813 to 969 (Fig. 5A). Competition ELISA experiments using mAbs 
directly conjugated to horseradish peroxidase (HRP) show that each mAb only competed with 
itself for binding to PvRBP2b, showing that 3E9, 6H1, and 10B12 bind to distinct epitopes in the 
N-terminal domain (Fig. 5B). Neither polyclonal nor monoclonal anti-PvRBP2b antibodies 
recognize recombinant PfRh4 and five other recombinant PvRBPs indicating that these 
antibodies are specific to PvRBP2b (fig. S12B) (19). Using flow cytometry, we show that 
addition of anti-PvRBP2b mAbs 3E9, 6H1 and 10B12 abolished the PvRBP2b161-1454 binding to 
reticulocytes, whereas anti-PvRBP2b mAb 8G7 and anti-PvRBP2a mAb 3A11 had no effect 
(Fig. 5C). 
We tested the ability of the anti-PvRBP2b antibodies to inhibit P. vivax invasion into 
human reticulocytes using a short-term P. vivax ex vivo assay with Brazilian and Thai clinical 
isolates (Fig. 5D, blue and black open dots respectively). As a control, we used a camelid anti-
Fy6 antibody which is a single monovalent VHH domain (15 kDa) (38, 39), that targets a surface 
exposed epitope on DARC and blocks its interaction with PvDBP. The addition of the 25 µg/ml 
camelid anti-Fy6 antibody in ex vivo assays using Thai isolates resulted in 85% inhibition of P. 
vivax invasion (Fig. 5D). Using four Thai isolates, the addition of inhibitory anti-PvRBP mAbs 
3E9, 6H1 and 10B12 at 25 µg/ml resulted in 49%, 45% and 42% inhibition of P. vivax invasion, 
respectively. To determine if inhibition could be improved by increasing the concentration of 
anti-PvRBP2b mAbs to match the molarity and valency of the single VHH domain, we used 125 
µg/ml of inhibitory anti-PvRBP2b mAbs. Under these conditions, we tested the invasion 
efficiency of two Brazilian isolates. We observed that addition of inhibitory anti-PvRBP mAbs 
3E9, 6H1 and 10B12 at 125 µg/ml resulted in 68%, 45% and 57% inhibition of P. vivax invasion 
in Brazilian isolates, respectively (Fig. 5D). To enable quantitative analyses of the ex vivo assays, 
we combined our initial results of Thai and Brazilian isolates at their respective mAb 
concentrations. We note that increased concentration of the inhibitory anti-PvRBP2b mAbs 
resulted in an equivalent or small increase in inhibition of P. vivax invasion (Thai at 25 µg/ml vs 
Brazilian at 125 µg/ml). Thus, our combined sample set underestimates the level of inhibition for 
antibody concentrations of 125 µg/ml. As additional controls, we included the non-inhibitory 
anti-PvRBP2b mAb 8G7 and an IgG1 mouse isotype control which displayed only 8% and 9% 
inhibition of P. vivax invasion, respectively (Fig. 5D). These results show that addition of anti-
PvRBP2b inhibitory mAbs 3E9, 6H1 and 10B12 resulted in significant reduction of P. vivax 
invasion compared to the non-inhibitory anti-PvRBP2b mAb 8G7 (Fig. 5D). 
We show that the inhibitory anti-PvRBP2b mAbs target a domain that appears to be 
under balancing selection (Fig. 2E and Fig. 5A), which may result in differences in inhibition 
between clinical isolates owing to the presence of polymorphic epitopes. To circumvent inter-
isolate differences, we further tested the combination of all three inhibitory mAbs, 3E9, 6H1 and 
10B12 pooled together (mAb pool) and polyclonal anti-PvRBP2b antibodies. The mAb pool 
resulted in significant 48% reduction in P. vivax invasion in both Thai and Brazilian isolates 
compared to anti-PvRBP2b mAb 8G7 (Fig. 5D). Addition of purified total IgG of polyclonal 
anti-PvRBP2b R1527 antibodies resulted in 53% reduction in P. vivax invasion whereas the 
rabbit prebleed IgG only showed only 5% inhibition (Fig. 5D). A previous study using rabbit 
anti-PvDBP antibodies shows that P. vivax invasion was reduced up to 64% (40), a level of 
inhibition comparable to what has been observed with our anti-PvRBP2b antibodies (Fig. 5D). 
These results show anti-PvRBP2b mAbs that block binding to reticulocytes also inhibit P. vivax 
invasion and highlight the important role of the PvRBP2b-TfR1 invasion pathway in P. vivax 
field isolates. 
Our results reveal a stable interaction between PvRBP2b and TfR1, and that anti-
PvRBP2b antibodies that block binding to reticulocytes also inhibit P. vivax invasion into human 
reticulocytes. P. vivax invasion is significantly inhibited in the presence of TfR1 mutant cells, 
showing that TfR1 is a critical host factor for entry into reticulocytes. We propose that the 
PvRBP2b-TfR1 interaction is important for the initial recognition of the target reticulocyte cells, 
which results in the commitment of P. vivax parasites for reticulocyte invasion and the 
subsequent engagement of PvDBP-DARC in tight junction formation leading to the successful 
completion of the invasion process. Identification of the molecular entities required for P. vivax 
invasion offer the possibility to target multiple invasion pathways for synergistic inhibition of P. 
vivax blood stage infection.  
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Fig. 1: PvRBP2b binds TfR1 on the reticulocyte surface. (A). PvRBP2b161-1454 binding in the 
presence of anti-TfR1 mAbs analysed by flow cytometry. Left: Dot plots of PvRBP2b161-1454 
binding (y-axis) to reticulocytes stained with thiazole orange (TO, x-axis). Right: normalized 
binding results where PvRBP2b161-1454 binding in the absence of mAbs was arbitrarily assigned 
to be 100%. (B) PvRBP2b161-1454 and PfRh428-766 binding were evaluated by flow cytometry with 
the addition of anti-TfR1 mAb OKT9 or CCP 1-3. PvRBP2b161-1454 and PfRh4 binding in buffer 
were arbitrarily assigned to be 100%. (C) Eluates of individual or mixtures of proteins immuno-
precipitated with anti-PvRBP2b mAb analyzed by SDS-PAGE. + or – indicates protein present 
or absent. Molecular weight marker (M). (D) Anti-TfR1 mAbs inhibit PvRBP2b-TfR1 complex 
formation in the FRET-based assay. The FRET signal was relative to “no mAb” control. (E) 
Binding of PvRBP2b161-1454 and PfRh428-766 in the presence of anti-TfR1 mAb MEM-189, CCP 
1-3 and MACV GP1. Left: dot plots showing PvRBP2b161-1454 (top) and PfRh428-766 binding 
(bottom). Right: normalized binding results where PvRBP2b161-1454 and PfRh428-766 binding in 
the presence of buffer was arbitrarily assigned to be 100%. (F) MACV GP1 inhibits 
PvRBP2b161-1454-TfR1 complex formation monitored by FRET assay. For (A), (B), (D), (E) and 
(F), Mean ± S.E.M., n ≥3, open dots represent biological replicates. Mann-Whitley test was used 
for (A) and (D) where MEM-75 was considered non-inhibitory and t-tests was used for (B), (E) 
and (F), * P ≤ 0.05, ** P ≤ 0.001.  
Fig. 2: Crystal structure of the N-terminal domain of PvRBP2b and its functional 
requirement. (A) Structure of the N-terminal domain of PvRBP2b from amino acid 169 to 470 
shown in two orthogonal views. (B) Electrostatic surface potential on the PvRBP2b structure. 
(C) Superimposition of the PvRBP2b structure (green) with PvRBP2a (purple) and PfRh5 
(orange). The PDB ID codes for PfRh5 and PvRBP2a are 4WAT and 4Z8N, respectively. (D) 
Crystal structure of the N-terminal domain superimposed with SAXS ab initio bead model of 
PvRBP2b169-470 (left) and PvRBP2b169-652 (right). (E) Sliding window analysis showing 
nucleotide diversity (π) values and Tajima’s D statistic in PvRBP2b. The grey box refers to a 
highly polymorphic region at amino acid positions 169 to 470 that appears to be under balancing 
selection. (F) Schematic representation of full-length PvRBP2b and recombinant protein 
fragments (left). Signal peptide (SP), transmembrane domain (TM) and N-terminal domain 
(yellow) are indicated. (G) PvRBP2b binding results by flow cytometry where PvRBP2b161-1454 
binding was arbitrarily assigned to be 100%. (H) Unlabeled recombinant PvRBP2b fragments or 
PfRh4 were mixed at 10-fold molar excess relative to the labeled PvRBP2b161-1454-TfR1 FRET 
pair. The FRET intensity was relative to buffer control. For (G to H), Mean ± S.E.M, n = 4, open 
dots represent biological replicates. The Mann-Whitley test was used to calculate the P value 
using the binding of 2b474-1454 that was considered no binding, * P≤ 0.05, ** P ≤ 0.001. 
Fig. 3: PvRBP2b binds to TfR1-Tf to form a stable ternary complex. PvRBP2b161-1454 (A) 
and PvRBP2b161-969 (B) were coupled covalently to a biosensor chip to probe binding of TfR1 
(concentration range assayed: 2 µM to 7.5 nM, top panels) and TfR1-Tf complexes 
(concentration range of TfR1-Tf complexes assayed: 2 μM:4 μM to 1.8 nM:3.9 nM (A) and 2 
μM:4 μM to 7.5 nM:15 nM (B), bottom panels). (C) and (D) Complex formation between 
PvRBP2b, TfR1 and Tf analyzed by analytical size exclusion chromatography (SEC). PvRBP2b-
TfR1-Tf ternary complex can be observed for PvRBP2b161-1454 (C, top panel) and PvRBP2b161-
969 (D, top panel). Two corresponding truncations of the N-terminal domain, PvRBP2b474-1454 
(C, bottom panel) and PvRBP2b474-969 (D, bottom panel) do not interact with the TfR1-Tf 
binary complex. The exclusion volume (V0) of the columns and the elution volumes of selected 
marker proteins are indicated with black arrowheads. Lower part: Coomassie-Blue stained 
SDS-PAGE gels of the fractions obtained from SEC. (E-F) Continuous sedimentation coefficient 
distributions derived from fitting sedimentation velocity data to a c(s) sedimentation model. (E) 
c(s) distributions for TfR1 (black line), Tf (magenta line) and PvRBP2b161-969 (blue line). (F) c(s) 
distributions for the TfR1-Tf complex (red line), and PvRBP2b161-969-TfR1-Tf complex (green 
line). 
Fig. 4: Deletions in TFRC reduce TfR1 surface expression, abolish PvRBP2b binding and 
inhibit P. vivax invasion. (A) Expression of TfR1, BSG and GYPA on the surface of jkRBCs, 
TfR1 mutants, ∆BSG null and cultured erythrocytes (cRBCs) as measured by flow cytometry. 
The right most panels show cytospin analysis of cells stained with May-Grünwald Giemsa 
staining technique. (B) TfR1∆G217 mutation in TfR1 abrogates PvRBP2b binding as observed 
using analytical SEC. (C) Quantitative surface proteomics demonstrate specific reduction in 
TfR1 protein levels in TfR1 mutants compared to wildtype jkRBCs. Levels of Tf, the binding 
partner for TfR1, are similarly reduced. Significance A was used to estimate p-values, and a 
minimum of 2 peptides were required for protein quantitation. (D) Binding of recombinant 
PvRBP2b fragments to jkRBCs, TfR1mutants, ∆BSG and cRBCs cells are shown in blue. 
Negative controls of unstained cells and isotype control stained cells are shown in the white and 
orange lines respectively. Compilation of results from PvRBP2b fragment binding to jkRBCs, 
TfR1 mutants, ∆BSG and cRBCs (right panel). Mean ± S.E.M, n = 3. (E) Comparison of 
invasion efficiency between jkRBCs and TfR1 mutant cell lines with either P. vivax or P. 
falciparum. The data shown are averages and the standard error of the mean from between four 
to five biological replicates shown as open dots. P value was calculated using a paired, two-tailed 
T test, **** P ≤ 0.0001 and ns is non-significant. 
Fig 5: Anti-PvRBP2b mAbs inhibit reticulocyte binding and P. vivax invasion in Brazilian 
and Thai clinical isolates. (A) ELISA plates were coated with equimolar concentrations of each 
recombinant fragment and detection with anti-PvRBP2b mAbs 3E9, 6H1, 8G7 and 10B12 are 
shown. (B) Competition ELISA using immobilized PvRBP2b incubated with un-conjugated anti-
2b mAbs (x-axis) and detected with 3E9-HRP, 6H1-HRP, 8G7-HRP and 10B12-HRP as 
indicated. For (A) and (B) error bars represent range showing the variability of duplicate 
measures. (C) PvRBP2b161-1454 binding in the presence of anti-PvRBP2b mAbs 3E9, 6H1, 8G7 
and 10B12 was analysed by flow cytometry. Normalized binding results where PvRBP2b161-1454 
binding in the absence of mAbs was arbitrarily assigned to be 100%. The anti-PvRBP2a mAb 
3A11 was used as a negative antibody control. Mean ± S.E.M, n = 5, open dots represent 
biological replicates. The Kruskal-Wallis test was used to calculate the P value using 8G7 
binding as no inhibition, *P ≤ 0.05, ***P ≤ 0.0001. (D) Invasion of P. vivax in Brazilian (blue 
open dots) and Thai (black open dots) clinical isolates in the presence of anti-PvRBP2b 3E9, 
6H1, 8G7 and 10B12, pooled mAbs (each mAb at one third of final concentration), mouse 
isotype control, purified rabbit prebleed IgG, purified total IgG of anti-PvRBP2b polyclonal 
antibody R1527 and camelid anti-Fy6 mAb. Antibodies were added in concentrations from 25 
µg/ml to 125 µg/ml except for the camelid anti-Fy6 mAb which was used at 25 µg/ml. Mean ± 
SD, n from 2 to 6, open dots represent biological replicates. For experiments with n > 2, we used 
the Kolmogorov-Smirnov test to compare 8G7 to 3E9, 6H1 and 10B12, *P ≤ 0.05, **P ≤ 0.001. 
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Materials and Methods 
PvRBP2b cloning and sequencing 
Sequence of PvRBP2b from P. vivax strain Salvador I was obtained from 
PlasmoDB Database (www.plasmodb.org; accession number: PVX_094255, total length 
2,806 amino acids). Synthetic DNA was codon-optimized for expression in E. coli (Life 
Technologies). The sequence encompassing amino acids 161 to 1,454 of PvRBP2b was 
cloned into pMA-RQ (ampR) vector. Restriction free cloning was used to generate 
shorter fragments of the protein following a protocol described before (41). PvRBP2b 
sequence including residues 161 to 969 and 161 to 1,454 as well as the corresponding 
truncations: 474 to 969 and 474 to 1,454, were cloned into modified version of pET-
32a(+) vector (Novagen) yielding constructs PvRBP2b161-969, PvRBP2b161-1454, 
PvRBP2b474-969 and PvRBP2b474-1454, respectively. These constructs allowed the 
expression of PvRBP2b proteins fused with bacterial thioredoxin, 6xHis-tag and tobacco 
etch virus (TEV) protease cleavage site at their N-termini. The TEV protease cleavage 
site enables removal of both tags. The construct used for crystallization, PvRBP2b169-470 
as well as PvRBP2b169-652 and PvRBP2b169-813 were cloned into pPROEX HTb vector and 
included N-terminal 6xHis-tag followed by a TEV cleavage site. All selected clones had 
their sequences verified at the Melbourne Translational Genomics Platform (MTGP). The 
list of all primer sequences used in this study is presented in Table S3 and a schematic 
representation of all PvRBP2b constructs is shown in Figure 2F. 
 
Expression and purification of different variants of PvRBP2b 
PvRBP2b169-470 was expressed using E. coli strain SHuffle® T7 (New England 
Biolabs) and Terrific Broth (TB) supplemented with 100 µg/ml of carbenicillin. Flasks 
containing 1 liter of medium were incubated in Multitron shaker (Infors HT) at 37°C at 
200 rpm. At OD600 of around 1.0, IPTG (Astral) was added to the final concentration of 
1.0 mM and protein expression was allowed to continue for 20 hours at 16°C. Cells were 
harvested by centrifugation at 6,000 x g, resuspended in freezing buffer containing 50 
mM TrisHCl pH 7.5, 500 mM NaCl, 10% (v/v) glycerol supplemented with cOmplete 
EDTA-free protease inhibitor cocktail (Roche), flash-frozen in liquid nitrogen and stored 
at -80°C until further processing.  
For the purification cell pellet was thawed on ice and resuspended in the freezing 
buffer supplemented with 0.5 mg/ml of DNase and 1.0 mg/ml of lysozyme (both from 
Sigma-Aldrich). Cells were lysed using sonicator Sonopuls UW 3200 (Bandelin) 
equipped with VS 70 T probe. The obtained crude cell extract was clarified by 
centrifugation at 30,000 x g for 45 minutes at 4°C. The supernatant was applied on the 5 
ml HisTrap column (GE Healthcare) pre-equilibrated with the freezing buffer. The 
unbound material was washed away using at least 10 column volumes of the washing 
buffer: 50 mM TrisHCl pH 7.5, 500 mM NaCl, 10% (v/v) glycerol and 10 mM 
imidazole. The bound protein was eluted from the column using the same buffer but 
containing 300 mM imidazole instead. The eluted fractions were pooled and dialyzed 
overnight in the presence of TEV protease into the buffer containing 20 mM NaHEPES 
pH 7.0 and 100 mM NaCl. The resulting protein sample was applied on the 5 ml SP-
Sepharose HiTrap column (GE Healthcare) pre-equilibrated with the dialysis buffer. 
Unbound material was washed away using at least 10 column volumes of the buffer. The 
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protein was eluted from the column using the gradient of 20 mM NaHEPES pH 7.0 and 
1.0 M NaCl. Collected fractions were analyzed on SDS PAGE and those containing the 
protein of interest were concentrated using Vivaspin 15 Turbo centrifugal concentrators 
(Sartorius) with a 5 kDa molecular weight cut-off and injected onto S75 Superdex 16/600 
size exclusion column (GE Healthcare) pre-equilibrated with 20 mM NaHEPES pH 7.5 
and 200 mM NaCl. The monodisperse peak fractions containing protein were pooled and 
concentrated using the same type of concentrator and used directly without freezing for 
the crystallization trials.  
Expression and purification of two longer variants of PvRBP2b, PvRBP2b161-969, 
PvRBP2b161-1454 as well as truncations, PvRBP2b169-652, PvRBP2b169-813, PvRBP2b474-969 
and PvRBP2b474-1454 were performed in a similar manner as described above or 
previously (18, 42). 
 
Cloning, expression and purification of recombinant PvRBPs 
Proteins included in this study were PvRBP1a (amino acids [aa] 160–1,170), 
PvRBP1b (aa 140–1,275), PvRBP2a (aa 160–1,135), PvRBP2b (aa 161–1,454), 
PvRBP2cNB (aa 501–1,300) and PvRBP2-P2 (aa 161–641) Their expression and 
purification have been described previously (18, 19, 42).  
 
Expression and purification of human transferrin receptor 1 
A construct encoding the soluble ectodomain of human transferrin receptor 1 
(TfR1, residues 121 to 760) was obtained from Addgene (pAcGP67A-TfR, Plasmid 
#12130, (43)). The TfR1 sequence follows a gene segment encoding the leader peptide 
from the baculovirus protein GP67, a 6xHis-tag, and a factor Xa cleavage site in a 
modified form of the pAcGP67A expression vector (Pharmingen) as described before 
(43). TfR1 was expressed in a lytic baculovirus/insect cell expression system using Sf21 
cells (Life Technologies) and Insect-XPRESS™ Protein-free Insect Cell Medium 
supplemented with L-glutamine (Lonza). Protein expression was induced by inoculation 
of the cell culture at around 1 x 106 cells/ml with the third passage stock (P3) of virus and 
typically allowed to progress for three days. Media supernatant was separated from the 
cells by centrifugation at 2,000 x g for 20 min and concentrated until around 10% (v/v) of 
their initial volume using tangential flow filtration device equipped in a cassette with 10 
kDa molecular weight cut-off (Millipore).  
Concentrated supernatants were subsequently dialyzed into a buffer containing 20 
mM TrisHCl pH 7.5 and 300 mM NaCl in order to remove the residuals of the culture 
media that might interfere with the subsequent steps of purification. After dialysis, 
protein was captured from the solution using Ni-NTA chromatography. The dialyzed 
sample was loaded onto 5 ml HisTrap column (GE Healthcare) pre-equilibrated with the 
dialysis buffer. Unbound material was washed away with at least 10 column volumes of 
the same buffer supplemented with 20 mM imidazole. Protein was eluted from the 
column with 300 mM imidazole in the dialysis buffer. Obtained sample was concentrated 
using Vivaspin 15 Turbo centrifugal concentrators (Sartorius) with a 5 kDa molecular 
weight cut-off and injected onto S200 Superdex 16/600 size exclusion column (GE 
Healthcare) pre-equilibrated with a buffer containing 20 mM NaHEPES pH 7.5, 100 mM 
NaCl and 50 mM NaHCO3. The final samples were supplemented with 10% (v/v) 
glycerol, flash-frozen in liquid nitrogen and stored at -80°C. 
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Expression and purification of TfR1 mutant DG217 
Synthetic DNA corresponding to the sequence of human TfR1 (residues 121 to 760) 
and harboring a Gly217 deletion was ordered from Life Technologies. The gene was 
multiplied using PCR and primers introducing BamHI and NotI restriction sites on its 
ends. The PCR product was digested with the corresponding restriction enzymes and 
ligated into pAcGP67A vector previously digested with the same enzymes. The sequence 
of the obtained clone was verified using Melbourne Translational Genomics Platform. 
The sequence of the obtained clone was identical with the wild-type except the 
introduced DG217 mutation. Expression and purification of the mutant protein were 
performed as described above for the wild-type TfR1 protein.  
 
Purification of human transferrin 
Apo-transferrin purified from human serum was purchased from Sigma-Aldrich 
(Catalog Number T4382). The protein powder was resuspended in a buffer containing 
100 mM disodium carbonate at pH 5.9. Loading of transferrin with iron was performed as 
described in the manufacturer’s leaflet by adding a solution of ferrous ammonium sulfate, 
hexahydrate (Sigma-Aldrich) corresponding to 2% (w/w) of protein mass. The sample 
was incubated with stirring for one hour at room temperature. The pH was then raised to 
8.5 using 1.0 M disodium carbonate and the solution was mixed for the additional two 
hours. Holo-transferrin was subsequently re-purified by gel filtration chromatography 
using a S200 Superdex 16/600 size exclusion column (GE Healthcare) equilibrated with 
20 mM NaHEPES pH 7.5, 100 mM NaCl and 50 mM NaHCO3 buffer. The final samples 
were supplemented with 10% (v/v) glycerol, flash-frozen in liquid nitrogen and stored at 
-80°C. 
 
MACV GP1 cloning, expression and purification 
MACV GP1 (Carvallo strain, residues 87-240) along with an N-terminal 6xHis-
tag, a TEV protease site, and a short linker (amino acids SGSG) was subcloned into the 
pHLsec vector (44). The protein was produced by transfection using linear 
polyethylenimine in GnTI-/- 293S cells grown in suspension and then purified using 
nickel affinity purification followed by reverse nickel affinity purification and size-
exclusion chromatography on a Superdex 200 column. 
 
Calculation of protein concentration 
Molecular weights and extinction coefficients for different variants of PvRBP2b 
protein were calculated using ProtParam from ExPASy server 
(http://web.expasy.org/protparam/). Molecular weights for transferrin and transferrin 
receptor 1 were obtained experimentally using Mass Spectrometry (MS) and their 
extinction coefficients were found in the literature (43, 45). All the values are presented 
in Table S4. 
 
TfR1-Tf and PvRBP2b161-969-TfR1-Tf complex formation 
The binary complex between Tf and TfR1 was created by mixing equimolar 
amounts of proteins and incubating them overnight at 4°C. The complex was 
subsequently re-purified by gel filtration chromatography using a S200 Superdex 16/600 
size exclusion column (GE Healthcare) equilibrated with 20 mM NaHEPES pH 7.5, 100 
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mM NaCl and 50 mM NaHCO3 buffer. The ternary complex between PvRBP2b161-969 and 
TfR1-Tf was created in an analogical way. 
 
Antibodies  
Anti-PvRBP polyclonal antibodies production was performed at the Walter and 
Eliza Hall Institute Monoclonal Antibody Facility (19). Rabbits were immunized five 
times with 150 µg of PvRBP2b161-1454. The first immunization was administered with 
Complete Freund’s adjuvant and the rest with Incomplete Freund’s Adjuvant. Rabbit IgG 
were purified from serum using Protein G sepharose.  
All anti-PvRBP mAbs were produced at the Monoclonal Antibody Facility at the 
Walter and Eliza Hall Institute. BALB/c and C57Bl6 mice received three immunizations 
of recombinant PvRBP2b161-1454. At day 0, Complete Freunds adjuvant was mixed with 
the antigen into an emulsion and injected intra-peritoneally. At day 30, and day 60, the 
antigen was mixed with incomplete Freunds adjuvant, and the emulsion injected intra-
peritoneally. Serum ELISA titrations were performed at day 72. The mouse with the best 
response received a final injection of antigen in saline, and splenocytes were harvested 
three days later. Spleen cells were fused with SP2/0 myeloma cells to form B-cell-
myeloma fused cells (hybridomas). Hybridomas were grown in hypoxanthine-
aminopterine thymidine growth medium. ELISA was used to select hybridomas 
producing antibodies specific to the immunized antigen. Hybridomas were cloned by 
limiting dilution in multi-well plates aiming for one cell or less per well. The sub-cloning 
supernatants were screened by ELISA. Two or more rounds of limiting dilution cloning 
were generally required before the hybridomas were deemed monoclonal. The antibodies 
were purified from monoclonal hybridoma supernatants with protein A sepharose. 
 Anti-TfR1 antibodies were obtained from the following suppliers: MEM-75 
(ab9179), 2B6 (ab38168), 23D10 (ab10251), LT71 (ab38446) and 13E4 (ab38171) from 
Abcam, OKT9 from Stemcell Technologies (60106), L01.1 (347510) and M-A712 
(555534) from BD Biosciences. For surface staining in Fig. 4A and Fig. S1A, we used 
the following antibodies anti-TfR1/CD71-APC (M-A712,1:20, BD Pharmigen 551374), 
anti-CR1/CD35-Alexa647 (E11, 1:100, BD Pharmigen 565329), GlyA-PE-Cy5 (JC159, 
1:1000, Abcam ab201309), anti-Basigin/CD147-APC (VJI/9, 1:20, Abcam ab91150), 
anti-DARC/CD234-APC (REA376, 1:100, Miltenyi Biotec 130105684) and anti-
DAF/CD55-PE-Cy5 (143-30, 1:100, Abcam ab25410). 
 
Reticulocyte enrichment for flow cytometry-based red blood binding 
500 ml of whole blood (Australian Red Cross) was passed through a RC high 
efficiency leucocyte removal filter (Haemonetics Australia) and washed three times with 
phosphate-buffered saline buffer (PBS) at 2,000 x g for five minutes to remove the serum 
component. Red blood cells were adjusted to approximately 50% haematocrit with PBS 
and 5.5 ml was carefully layered on 6 ml of 70% (v/v) isotonic Percoll cushion (GE 
Healthcare). After centrifugation at 2,000 x g for 25 minutes, a thin band of enriched 
reticulocytes at the Percoll interface was collected. Reticulocytes were stored in RPMI 
wash buffer (Gibco) at 4°C until further usage. 
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Enzymatic treatment of red blood cells  
Red blood cells were treated with trypsin (Sigma-Aldrich), chymotrypsin 
(Worthington) and neuraminidase (Sigma-Aldrich). 480 µl of packed blood was washed 
with 12 ml of wash buffer (RPMI HEPES medium with 25 mM NaHCO3), spun down at 
2,000 x g for one minute and resuspended in 12 ml of wash buffer. 2 ml of the 
resuspension was used for each sample (i.e. untreated, high trypsin, low trypsin, 
chymotrypsin and neuraminidase). Samples were spun down at 2,000 x g for 1 minute 
and the wash buffer was removed. Packed blood (~80 µl) was treated with 2 ml of the 
various enzymes at the following concentrations, high trypsin (1 mg/ml), low trypsin (0.1 
mg/ml), chymotrypsin (1 mg/ml) and neuraminidase (0.07 U/ml). Samples were 
incubated at 37oC for 1 hour and washed with 4 ml of wash buffer. Wash buffer was 
replaced with 1 ml of chymotrypsin/trypsin inhibitor (Worthington) at 1 mg/ml and 
incubated for 10 minutes. Samples were washed and stored in 4 ml of wash buffer at 4oC. 
 
Flow cytometry-based red blood cell binding assay 
Reticulocyte preparations were resuspended in PBS to a final a final volume of 1 x 
107 cells/ml. Recombinant proteins were incubated at 0.01 mg/ml in 100 µl of the 
resuspended reticulocyte population for an hour at room temperature. All washes were 
performed in PBS supplemented with 1% (w/v) bovine serum albumin (BSA) and spun at 
4,000 x g for 1 minute and all antibody incubations were performed at room temperature 
for one hour. The binding assays were washed once and incubated with the respective 
rabbit polyclonal antibodies (12.5 µg/ml). After washing, Alexa Fluor 647 chicken anti-
rabbit secondary antibody (1:100; Life Technologies) was added. After a final wash, 100 
µl thiazole orange (TO) (Retic-Count Reagent; BD Biosciences) was added and 
incubated for half an hour. The TO stain was removed and red blood cells were 
resuspended in 200 µl PBS and analysed on the FACSCalibur flow cytometer (BD 
Biosciences). 50,000 events were recorded and results were analysed using FlowJo 
software (Three Star). The background signal from a rabbit polyclonal antibody and 
Alexa Fluor 647 conjugated antibody control (without protein) was subtracted from all 
binding results. To enable comparison between biological repeats, percentage binding of 
the protein in the presence of inhibitors/mAbs was divided by the percentage binding 
with no inhibitor/no mAbs and multiplied by 100 to get the percentage binding relative to 
the no inhibitor control. For our inhibition studies, anti-TfR1 antibodies were added at 
0.05 mg/ml, MACV GP1 at 0.5 mg/ml and CCP 1-3 at 0.3 mg/ml. 
 
Immunoprecipitation experiments 
Immunoprecipitation assays were performed using 0.25 mg/ml of both PvRBP2b161-
1454 and TfR1-Tf complex and 0.05 mg/ml of anti-PvRBP2b mAb in 100 µl reaction 
volume in PBS. After one hour incubation at 4°C on rollers, 10 µl of packed Protein G-
sepharose beads was added to bind anti-PvRBP2b mAbs and incubated overnight at 4°C 
on rollers. Beads were washed three times in PBS and spun down at 2,000 x g for two 
minutes. Anti-PvRBP2b mAbs and associated proteins were eluted from beads by boiling 
for five minutes in 2x SDS-PAGE reducing sample buffer and analysed on 4-12% Bis-
Tris gels (Invitrogen). Protein bands were visualized by staining with SimplyBlue 
SafeStain (Life Technologies). 
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Fluorescence resonance energy transfer (FRET) assay 
PvRBP2b161-1454 and TfR1 were labelled with N-hydroxysuccinimide ester-activated 
DyLight 488 (DL488) and DyLight 594 (DL594) (Life Technologies) respectively. The 
dyes were dissolved in dimethyl sulfoxide (DMSO) (Sigma) and added at five-fold molar 
excess to the protein being labelled. After one hour incubation at room temperature, un-
conjugated dye removed using a Micro Bio-Spin P-6 column (BioRad) at 1,000 x g for 
two minutes. Average dye per protein was ~3.5 dye/protein for PvRBP2b161-1454 and ~1.8 
dye/protein for TfR1. PvRBP2b161-1454-DL488, TfR1-DL594 and Tf were mixed in a 
1:1:1 molar ratio with excess of candidate inhibitor in a final 10 µl of reaction volume in 
FRET buffer read in 384-well plates (Corning). One µl of 1% (w/v) SDS was added to 
one well to measure background signal. Fluorescence intensity was measured using 
EnVision plate reader (PerkinElmer Life Sciences). DL488 (donor) fluorescence was 
measured with a 485/14-nm excitation filter and 535/25-nm emission filter and DL594 
(acceptor) fluorescence was measured with a 590/20-nm excitation filter and 615/9-nm 
emission filter. Sensitized emission was measured with a 485/14-nm excitation filter and 
615/9-nm emission filter. 
 
Generation of TfR1 mutant JK-1 cells 
The erythroleukemia cell line JK1 was used to generate CRISPR/Cas9-based 
deletions of TFRC (46). Briefly, JK1 cells were maintained in an undifferentiated state in 
JK1 growth media: Iscove’s Modified Dulbecco’s Medium (IMDM) with Glutamax 
(ThermoFisher), 0.5% (v/v) penicillin/streptomycin (ThermoFisher), 10% AB+ 
octoplasLG (OctoPharma), 2 IU/ml heparin (Affymetrix) and 10 µM tranylcypromine 
(Cayman Chemicals). Cells were transduced with a lentivirus containing the Cas9 
expression plasmid LentiCas9-Blast (47) and selected for with 6 µg/ml blasticidin 
(Sigma-Aldrich) to produce JK-1-Cas9. GuideRNAs (sgRNAs) targeting TFRC were 
identified using the Broad Institute Genetic Perturbation Platform sgRNA designer tool 
(48) and the four top gRNAs were selected: TFRC-g1 (Broad ID: TFRC_196074043_s) 
5′-CAGGAACCGAGTCTCCAGTG; TFRC-g2 (Broad ID: TFRC_196072124_s) 5′-
AAATTCATATGTCCCTCGTG; TFRC-g3 (Broad ID: TFRC_196071432_as) 5′-
GGGGGTTATGTGGCGTATAG; TFRC-g4 (Broad ID: TFRC_196068088_s) 5′-
AATTGGTGTGTTGATATACA. The sgRNA sequences were cloned into LentiGuide-
Puro (47) following which lentivirus containing the vector was produced (49). The 
lentivirus was transduced into the JK-1-Cas9 line and the cells were selected on both 
blasticidin and 2 µg/ml puromycin (Sigma-Aldrich).  
 Expression of TfR1 on the transduced cells was monitored by flow cytometry 
using a Milteny MACSQuant instrument with 405 nm, 488 nm and 638 nm lasers 
(Miltenyi Biotec), following staining with a 1 in 20 dilution of α-TfR1-APC (Miltenyi 
Biotech, San Diego, CA) for 30 minutes at room temperature in PBS + 0.5% BSA. 
Within 2-3 weeks post transduction, a TfR1-negative population was observed only with 
the TFRC-g3 sgRNA. Single cell clones were obtained by limiting dilution and the 
CRISPR/Cas9 target region was PCR amplified using the following primers: TFRC-g3-F 
5′-GGTAAATTTCCTCAAGCCAAA and TFRC-g3-RC 5′-
CAGGACATGGGGAAAGTGAT. The size and location of the indel was determined by 
Tracking of Indels by Decomposition (TIDE) analysis (50). Two clones (TfR1 mut1 and 
TfR1 mut 2) were used for subsequent experiments. 
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Induction of jkRBCs for TfR1 binding studies 
Wild-type and mutant (TfR1 mut1 and TfR1 mut2) cell lines were induced to 
differentiate using epigenetic factor PFI-1. Briefly, cells were expanded in JK-1 growth 
media and to start induction cells were washed and resuspended in JK1 differentiation 
media: Iscove’s Modified Dulbecco’s Medium (IMDM) with Glutamax (ThermoFisher), 
0.5% (v/v) penicillin/streptomycin (ThermoFisher), 10% AB+ octoplasLG 
(OctoPharma), 2 IU/ml heparin (Affymetrix), 330 µg/ml human holotransferrin (Scipac) 
and 2 µM PFI-1 (Cayman Chemicals). Cells were differentiated for between 12-14 days 
and media changes were made every 4-5 days. Differentiation into jkRBCs was validated 
by staining for GypA with a 1 in 100 α-GypA-FITC (StemCell Technologies) and BSG 
with 1 in 100 α-BSG-FITC (Thermo Fisher Scientific, USA), followed by flow 
cytometry. Cytospins were prepared as described (51). 
 
Quantitative surface proteomics 
We adapted our previously described method (51, 52). Briefly, 2 × 107 of each 
cell type were washed with PBS and then surface sialic acid residues were chemically 
biotinylated following oxidation with sodium meta-periodate (Thermo) and reaction with 
aminooxy-biotin (Biotium). After quenching the reaction with 5 mM glycerol in PBS 
(Sigma-Aldrich), cells were incubated in Triton X-100 lysis buffer. Streptavidin agarose 
beads (Pierce) were used to enrich for biotinylated glycoproteins, and after extensive 
washing, the captured proteins were denatured with dithiothreitol (Sigma-Aldrich), 
alkylated with iodoacetamide (IAA, Sigma) and digested on-bead with trypsin (Promega) 
in 200 mM sodium HEPES pH 8.5 for 3 hours. The tryptic peptides were recovered and 
labeled with tandem mass tag (TMT) reagents (52). Following quenching with 
hydroxylamine, the TMT-labeled samples were combined in a 1:1:1:1 ratio, enriched and 
desalted and then 75% of the total sample was separated into 6 fractions using tip-based 
strong cation exchange columns (52). Of the remaining 25% of the total sample, a portion 
(10% of total sample) was subject to mass spectrometry unfractionated.  
Mass spectrometry data was acquired using an Orbitrap Fusion coupled with a 
UltiMate 3000 Nano LC (Thermo Fisher Scientific). Peptides were separated using a 90 
min linear gradient of 3 to 33% (v/v) acetonitrile in 0.1% formic acid at a flow rate of 
200 nl/min (fractionated samples) or a 180 min gradient with otherwise identical 
parameters (unfractionated sample), and the separation was done on a 75 cm PepMap 
C18 column (Thermo Fisher Scientific). Each analysis used a MultiNotch MS3-based 
TMT method (52, 53). The scan sequence began with an MS1 spectrum (Orbitrap 
analysis, resolution 120,000, 400-1400 Th, AGC target 2 x 105, maximum injection time 
50 ms). MS2 analysis consisted of CID (quadrupole ion trap analysis, AGC 15,000, NCE 
35, maximum injection time 120 ms). The top ten precursors were selected for MS3 
analysis, in which precursors were fragmented by HCD prior to Orbitrap analysis (NCE 
55, max AGC 2 x 105, maximum injection time 150 ms, isolation specificity 0.5 Th, 
resolution 60,000). A Sequest-based in house software pipeline was used to process mass 
spectra as previously described (52). The human Uniprot database (April 2014) was used 
to search for proteins and samples were concatenated with common contaminants (52) 
and filtered to a final protein-level false discovery rate of 1%. In order to compare signals 
between different TMT channels, TMT reporter ion counts across all peptide-spectral 
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matches were summed using in-house software as previously described (52). Poor quality 
MS3 spectra with a combined signal:noise ratio < 250 across all TMT reporter ions were 
excluded. For protein quantitation, reverse and contaminant proteins were removed, then 
each reporter ion channel was summed across all quantified proteins and normalized 
assuming equal protein loading across all samples. Fold change for each protein was 
calculated according to (average signal:noise (TfR1 mutants) / average signal:noise (JK-1 
controls). Protein quantitation values were exported for further analysis in Excel. Gene 
Ontology Cellular Compartment terms were downloaded from www.uniprot.org and p-
values (Significance A) calculated and adjusted with the Benjamini Hochberg method 
using Perseus version 1.2.0.16 (54). 
 
Crystallization of PvRBP2b169-470 
Crystallization screens were set up at the Collaborative Crystallization Center in 
Parkville using crystallization robot Phoenix (Art Robbins Instruments) and sitting drop 
vapor diffusion method in 96-well format plates. 150 nl of protein sample at two different 
concentrations, 7.5 and 15.0 mg/ml, were mixed with the reservoir in 1:1 ratio. Two 
different sparse matrix screens were set up covering wide range of different 
crystallization conditions. Plates were incubated at 20°C and drops were monitored 
regularly over the period of 3 months. First crystals appeared after 24 hours in the 
condition containing 20% (w/v) PEG 3,350, 200 mM potassium thiocyanate and 100 mM 
Bis-Tris pH 7.5. The initial crystal hit was optimized manually using the hanging drop 
method, 24-well Linbro plates (Hampton Research) and varying pH and PEG 
concentration. For data collection crystals were cryo-protected in a reservoir solution 
supplemented with 20% (v/v) glycerol and frozen in liquid nitrogen. 
 
X-ray diffraction data collection and structure determination 
Diffraction data were collected at MX2 microfocus beamline at the Australian 
Synchrotron Facility in Clayton at 0.9537 Å wavelength using ADSC Quantum 315r 
detector. The best crystal diffracted to 1.71Å resolution and belonged to the primitive 
monoclinic space group P21 with cell dimensions a = 59.50 Å, b = 124.20 Å, c = 65.31 Å, 
a = 90.00°, b = 97.75° and g = 90.00°. The collected diffraction data were integrated 
using iMosflm (55). Scaling and merging were performed using program Aimless from 
the CCP4 package (56).  The cell content was analyzed using program Matthews (57). 
Molecular replacement was attempted using Phaser (58) and PvRBP2a as a model (PDB 
accession number 4Z8N). The search yielded a definitive solution containing two 
molecules in the asymmetric unit. The initial model was rebuilt automatically using 
program AutoBuild (59) followed by a manual improvement using program Coot (60). 
The structure was refined using the program Phenix Refine (59) and including TLS that 
were generated using TLSMD web server (61). Multiple cycles of model building and 
atomic refinement yielded a structure that was eventually refined to 1.71 Å resolution 
with the final Rwork = 0.168 and Rfree = 0.188. The refinement statistics are given in Table 
S1. The atomic coordinates and structure factors have been deposited in Protein Data 
Bank with accession number 5W53. 
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Analytical size exclusion chromatography (SEC) 
Analytical chromatography was performed at room temperature using ÄKTA 
pure 25 M1 chromatographic system (GE Healthcare). Proteins were separated alone as 
well as mixed in all possible combinations. In order to facilitate the analysis, proteins 
were mixed in equimolar ratio and the same amount of given protein was used throughout 
the experiment. Samples were incubated for 1 hour to allow complex formation and then 
100 µl were injected onto Superdex 200 Increase 10/300 GL column (GE Healthcare) 
equilibrated with 20 mM NaHEPES pH 7.5, 100 mM NaCl, 50 mM NaHCO3 at 0.75 
ml/min of buffer flow. The absorbance of the eluent was monitored at 280 nm. The eluate 
was collected in 0.5 ml fractions. Obtained fractions were analyzed using SDS PAGE. 
The column was calibrated with high- and mid-mass molecular mass markers (GE 
Healthcare) as described in the manufacturer’s instructions. The results of the calibration 
are shown in Figure S5. 
 
Surface plasmon resonance (SPR) data collection, processing and analysis 
All experiments were carried out at 25°C using a Reichert SR7500DC SPR 
instrument (Reichert Technologies, Buffalo, NY) using the integrated SPR autolink 
software package. Data analysis was performed using the TraceDrawer software package 
(Ridgeview Instruments AB). The running buffer consisted of 20 mM NaHEPES at pH 
7.5 including 100 mM NaCl, 50 mM NaHCO3 and 0.005% (v/v) Tween 20 and was used 
for the SPR experiments that probe the interactions with TfR1. To analyze the 
interactions of TfR1 and TfR1-Tf complexes with PvRBP2b, 4,300 RUs of the fragment 
PvRBP2b161-969 or 1,300 RUs of the fragment PvRBP2b161-1454 were covalently fixed to a 
carboxymethyldextran hydrogel biosensor chip (CMD500m, purchased from XanTec 
Bioanalytics, Duesseldorf, Germany) using standard amine coupling according to the 
manufacturer’s instructions. The reference surface was blank immobilized. To probe 
binding, a concentration series of TfR1 or TfR1-Tf complexes was injected (as indicated) 
at 25 µl/min for 2 min followed by buffer flow for 5 min and a regeneration step 
consisting of an injection of 1.0 M NaCl for 30 s. The TfR1 concentration of 7.5 nM or 
the 7.5:15 nM mixture of the TfR1-Tf complex was injected twice to assess 
reproducibility. Reference subtracted sensorgrams of two-fold dilution series are shown. 
For Fig. 3A, 1,300 RUs of PvRBP2b161-1454 were coupled covalently to a 
carboxymethyldextran hydrogel biosensor chip to probe binding of TfR1 and TfR1:Tf 
complexes. Soluble TfR1 was assayed in a concentration range from 2 µM to 7.5 nM, 
whereas soluble TfR1:Tf complexes were assayed in a range from 2 µM:4 µM to 1.8 
nM:3.9 nM. For Fig. 3B, 4,300 RUs of PvRBP2b161-969 were coupled covalently to a 
carboxymethyldextran hydrogel biosensor chip. Soluble TfR1 binding is shown for a 
concentration series ranging from 2 µM to 7.5 nM and the concentration range of TfR:Tf 
complexes range from 2 µM:4 µM to 7.5 nM:15 nM.  
To probe the interaction with anti-PvRBP2b monoclonal antibodies (mAbs) 
PvRBP2b161-1454 was immobilised via standard amine coupling onto 
carboxymethyldextran sensorchips (CMD500m, Xantec bioanalytics) and 3E9, 6H1 and 
10B12 mAbs were flown over the surfaces at the concentrations 40, 52 and 40 nM, 
respectively. As running buffer, 10 mM NaHEPES pH 7.4 with 150 mM NaCl, and 
0.005% (v/v) Tween 20 was used throughout. The antibodies 3E9 and 10B12 were 
analysed on a single PvRBP2b161-1454 surface with 10,000 RU of the protein being coated. 
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Apart for 10B12 extensive buffer flow of up to 12 h in between cycles was sufficient to 
substantially dissociate the antibody-PvRBP2b complexes. The 6H1 mAb was assayed on 
another CMD500 chip coated with 1,300 RU of PvRBP2b161-1454. The binding curves 
were fit to a bivalent (2:1) interaction model using the TRACEDRAWER software 
package to estimate affinity constants for the bivalent interaction. Table S6 summarizes 
the corresponding kinetic parameters (ka and kd), the equilibrium dissociation constants 
(KD1 and KD2) and the c2 values of goodness of the fit. 
 
Small angle X-ray scattering (SAXS) data collection, processing and analysis 
SAXS data were collected on the SAXS/WAXS beamline at the Australian 
Synchrotron using the inline size-exclusion chromatography setup and processed as 
described previously (62). 2D scattering data were radially averaged, normalized to 
sample transmission and an average of background scattering profiles was subtracted 
using the ScatterBrain software (written by Stephen Mudie, Australian Synchrotron). The 
ATSAS suite of software was used for all subsequent SAXS data analyses. For an initial 
assessment of data quality, Guinier analysis was performed using PRIMUS (63). The 
program GNOM (64) applied an indirect Fourier transform to the scattering profile to 
calculate the pair-wise intra-atomic distance distribution function P(r) and Dmax, the 
maximum dimension of the particle. Theoretical scattering curves were calculated from 
atomic coordinates and compared with experimental scattering curves by using CRYSOL 
(65). Low-resolution shape envelope was generated with the ab initio bead-modeling 
program DAMMIF (66), by performing 20 independent reconstructions, aligning all with 
the most probable model with DAMSEL and DAMSUP, averaging models with 
DAMAVER and adjusting to correspond with the experimentally determined excluded 
volume with DAMFILT (67).  
The crystal structure of PvRBP2b169-470 was fitted into the obtained SAXS 
envelope using rigid-body search and program COLORES (68). The program returned 
four individual models that were subsequently judged based on the value of the 
correlation coefficient given for each model as well as the agreement with the available 
biological information (sequence of the residues constituting the protein fragment and the 
predicted direction of the polypeptide chain). The results of the superimposition were 
visualized using PyMOL (69). The data collection and processing statistics are presented 
in Table S2. 
 
Analytical ultracentrifugation (AUC) data collection, processing and analysis 
Samples were analysed using an XL-I analytical ultracentrifuge (Beckman 
Coulter, Fullerton, CA) equipped with an AnTi-60 rotor. Radial absorbance data were 
acquired at 20°C using a rotor speed of 50,000 rpm (201,600 x g) and a wavelength of 
280 nm, with radial increments of 0.003 cm. The sedimenting boundaries were fitted to to 
a continuous sedimentation coefficient distribution [c(s)] model with SEDFIT (70), using 
a regularization parameter of p = 0.95, floating frictional ratios, and 250 sedimentation 
coefficient increments in the range of 0-20 S. The partial specific volumes of proteins, 
buffer density, and buffer viscosity were calculated using SEDNTERP (71). 
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Circular dichroism (CD) data collection, processing and analysis 
CD data were collected using circular dichroism spectrometer Model 410 (Aviv 
Biomedical) and analyzed as described before (18). Before the experiment, protein 
samples were dialyzed extensively overnight into 20 mM NaHEPES pH 7.5, 100 mM 
NaCl, 50 mM NaHCO3 buffer.  For the measurements, the protein concentration was set 
to 3.0 µM. The CD spectra were recorded between 260 and 190 nm with 1 nm 
wavelength step and 4 s averaging time at 25°C.  120 µl of the protein sample was using 
quartz cell (Hellma) with the optical path of 0.05 cm. After subtracting the background 
from the buffer the spectra were processed using DichroWeb server (72, 73). The 
experimental data were converted to mean residue molar ellipticity (q). The content of 
secondary structures was predicted using CDSSTR algorithm (74) and SMP180 reference 
set (75) for 190-240 nm.   
 
Secondary structures predictions 
 Secondary structures predictions for PvRBP2b were performed using JNet 
Secondary Structure Prediction algorithm integrated into Jalview 2.10.1 (76).  
 
Population genetic analyses 
We downloaded genotype data from https://www.malariagen.net/data/p-vivax-
genome-variation-may-2016-data-release and extracted variants from the coding region 
of PvRBP2b using bcftools 1.3.1.  We converted the VCF to a diploid VCF (changing 0 
and 1 to 0/0 and 1/1 respectively) using sed commands. We calculated nucleotide 
diversity and Tajima’s D using scikit-allel 1.1.8. To give the most accurate estimate of 
true diversity we used all SNPs discovered within the gene, including those that failed 
variant filters. Code used can be found at 
https://github.com/podpearson/PvRBP2b/blob/master/20170803_RBP2b_diversity_for_
Wai-Hong.ipynb 
 
Detection of PvRBPs and PfRh4 by polyclonal and monoclonal antibodies by ELISA 
96-well flat-bottomed plates (Maxisorp; Nunc) were coated with 65 nM of 
recombinant PvRBP1a, PvRBP1b, PvRBP2a, PvRBP2b, PvRBP2cNB, PvRBP2-P2 or 
PfRh4 fragments in 100 ul of PBS at 4°C overnight. All washes were done three times 
using PBS/0.1% Tween and all protein and antibody incubations were performed for one 
hour at room temperature. Coated plates were washed and blocked with 10% (w/v) skim 
milk solution (Devondale) for one hour at room temperature. After blocking, primary 
monoclonal or polyclonal antibodies were added (0.001 µg/µl), washed and subsequently 
incubated with horseradish peroxidase (HRP)-conjugated rabbit anti-mouse or HRP-
conjugated goat anti-rabbit secondary antibody (1:1000 or 1:200 respectively; Fisher 
Scientific). The primary mAbs were against PvRBP1a (4E3), PvRBP1b (4G4), PvRBP2a 
(3A11), PvRBP2b (3E9, 6H1, 8G7 and 10B12), PvRBP2cNB (6H2), PvRBP2-P2 (9E3) 
and PfRh4 (10C9). Plates were washed twice with PBS/0.1% Tween and a final wash 
with PBS to remove residual Tween. 100 µl of azino-bis-3-ethylbenthiazoline-6-sulfonic 
acid (ABTS liquid substrate; Sigma) was added and incubated in the dark at room 
temperature for approximately three minutes. 100 µl of 1% (w/v) SDS was used to stop 
the reaction. Absorbance was read at 405 nm and all samples were performed in 
duplicate. 
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P. vivax ex vivo invasion assay 
In general, the ex vivo assays using Thai and Brazilian isolates were performed by 
incubating mature parasites with TfR1-positive enriched reticulocytes in either the 
absence or in the presence of up to 125 µg/ml of anti-PvRBP2b mAbs 3E9, 6H1, 8G7 
and 10B12, 125 µg/ml pooled anti-PvRBP2b mAbs (3E9, 6H1 and 10B12; each mAb in 
the pool was at one third of the final concentration), 125 µg/ml anti-PvRBP2b polyclonal 
antibody R1527, 125 µg/ml mouse isotype control (ThermoFisher MA1-10407), 125 
µg/ml rabbit prebleed IgG (Abcam, ab176094) or 25 µg/ml of a camelid anti-Fy6. For the 
rabbit polyclonal antibodies, R1527 and the prebleed control were both protein A purified 
total IgG. Since the camelid anti-Fy6 antibody is a single monovalent VHH domain (15 
kDa), it was added at 25 µg/ml to match molar concentration and valency of the other 
conventional antibodies. 
The ex vivo invasion assays used in this study for Thai isolates has been described 
previously (20, 77). Selection of the late developmental stages of P. vivax was performed 
using the magnetic-activated cell sorting (MACS) system (Miltenyi). Mature parasites 
were mixed with TfR1-positive enriched reticulocytes in in either the absence or in the 
presence of up to 125 µg/ml of anti-PvRBP2b mAbs 3E9, 6H1, 8G7 and 10B12, 125 
µg/ml of pooled anti-PvRBP2b mAbs (3E9, 6H1 and 10B12) or 25 µg/ml of a camelid 
anti-Fy6 antibody. Enriched reticulocytes and mature P. vivax schizonts were incubated 
together for 24 hours, and newly infected red blood cells were determined by 
microscopy. The Thai clinical samples used in this study were collected from P. vivax 
infected patients and healthy donors for the cord blood attending the clinics of the Shoklo 
Malaria Research Unit (SMRU), Mae Sot, Thailand, under the following ethical 
guidelines in the approved protocols; OXTREC 45-09 and OXTREC 17-11 (University 
of Oxford, Centre for Clinical Vaccinology and Tropical Medicine, UK) and MUTM 
2008-215 from the Ethics committee of Faculty of Tropical Medicine, Mahidol 
University.  
For the ex vivo assays using Brazilian isolates, TfR1-positive reticulocytes were 
enriched from packed O+ peripheral blood from Caucasian donors (Valley Biomedical, 
USA) as described previously with the following modifications (78). Briefly, RBCs were 
first centrifuged at 4,000 x g for 2 hours, following which the top 20% of cells were 
recovered. These cells were layered on a KCl-Percoll gradient (between 1.078 – 1.084 
g/ml) and the cells at the interface were recovered and washed multiple times with 
incomplete RPMI 1640 medium (ThermoFisher, USA). White blood cell contaminants 
were removed by passing cells through a 45% (v/v) KCl-Percoll gradient, following 
which the reticulocyte-enriched pellet fraction was recovered and washed with RPMI 
1640 medium. Cells were resuspended in Iscove’s Modified Dulbecco’s Medium 
(ThermoFisher, USA) and CD71 microbeads (Miltenyi Biotec, USA) were added 
according to the manufacturer’s instructions. Cells and microbeads were incubated with 
rotation overnight at 4°C. Next the cells were washed to remove excess microbeads and 
then loaded onto an AutoMACS instrument (Miltenyi Biotec, USA). TfR1-enriched cells 
were recovered, washed and the proportion of TfR1-positive cells was determined via 
flow cytometry using anti-TfR1-APC (Miltenyi Biotec, USA). Enrichment was generally 
> 80% TfR1-positive.  
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Frozen Brazilian P. vivax isolates were thawed and enriched using 1.080 g/ml 
KCl-Percoll gradients. Parasites were subsequently cultured in Iscove’s Modified 
Dulbecco’s Medium (ThermoFisher, USA) supplemented with 10% (v/v) heat-
inactivated AB+ human serum and 0.25 mg/ml gentamycin (ThermoFisher, USA) at 
37°C in parasite culture gas (94% nitrogen, 5% carbon dioxide, 1% oxygen) for 40 hours. 
Schizontemia was determined via slide microscopy and the cell density via 
hemocytometer counting. Schizontemia levels were generally between 0.5 – 1.0%. 
Invasion assays were set up in half-area 96-well plates (Corning, USA) with 1.0 x 106 P. 
vivax donor cells plus 1.0 x 106 acceptor cells (either TfR1-positive reticulocytes or JK1 
cells) in a total of 100 µl of AIM V medium (ThermoFisher, USA) supplemented with 
10% (v/v) AB+ human serum and 0.25 mg/ml gentamycin (Sigma-Aldrich, USA). Where 
appropriate, assays with Brazilian isolates were supplemented in the absence or presence 
of preservative-free antibodies of 125 µg/ml of anti-PvRBP2b mAbs 3E9, 6H1, 8G7 and 
10B12, 125 µg/ml pooled anti-PvRBP2b antibodies (3E9, 6H1 and 10B12), 125 µg/ml 
anti-PvRBP2b polyclonal antibody R1527, 125 µg/ml mouse isotype control 
(ThermoFisher MA1-10407), 125 µg/ml rabbit prebleed IgG (Abcam, ab176094). 
Invasion was allowed to proceed for ~ 20 hours at which point cytospins were made 
(ThermoFisher, USA). Cells were stained either with Hemacolor II stain (Sigma-Aldrich, 
USA) or May-Grünwald-Giemsa (Sigma-Aldrich, USA) and parasitemia was determined 
by slide microscopy using a Miller reticle and whole-field counting as described (79). 
Slides were counted until a minimum of 20 newly-invaded ring-stage parasites had been 
observed. For each experiment data were collected from between 2 – 3 technical 
replicates. Study protocols for parasite sample collection in Brazil were approved by the 
Institutional Review Board of the Institute of Biomedical Sciences, University of São 
Paulo, Brazil (936/CEP, 2010 and 1169/CEPSH, 2014). Written informed consent was 
obtained from all patients. 
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Figure S1. Flow cytometry-based analysis of PvRBP2b binding and receptor surface 
expression. (A) Dot plots of PvRBP2b binding and surface expression for glycophorin A 
(GYPA), basigin, DARC, CR1, Decay Accelerating Factor (DAF) and TfR1 were 
analyzed by flow cytometry on reticulocytes treated with low or high amounts of trypsin 
(LT or HT), chymotrypsin (CHY) or neuraminidase (Nm). Reticulocytes were stained 
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with thiazole orange (TO, x-axis). (B) Compiled PvRBP2b binding results and surface 
expression staining. (C) Dot plots of PvRBP2b, PvRBP2a and PfRh4 binding together 
with surface staining for CR1 (top panel) and TfR1 (bottom panel) were analyzed by flow 
cytometry on reticulocyte-enriched populations. These data show that PfRh4 binding is 
correlated with CR1 levels and PvRBP2b binding is correlated with TfR1 levels. (D) Dot 
plots of surface receptor expression of TfR1, CR1 and unstained cells (top panels) and 
reticulocytes with bound PvRBP2b, PvRBP2a and PfRh4 binding alone (bottom panel) 
were analyzed by flow cytometry on reticulocytes. These data shows no bleed through 
between the channels. 
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Figure S2. Specificity of the interaction between PvRBP2b and TfR1-Tf. (A) 
PvRBP1a (117 kDa), PvRBP1b (133 kDa), PvRBP2a (114 kDa) and PvRBP2b (153 kDa) 
were immunoprecipitated with their respective mAbs in the presence of the binary 
complex TfR1-Tf. Molecular weight marker (M) labeled in kDa. Eluates were run under 
reducing conditions on a SDS-PAGE gel and stained with SimplyBlue SafeStain. 
Multiple bands in the lanes with PvRBP alone suggest protein degradation or 
contaminating proteins from the purification of these PvRBPs that may bind non-
specifically. P, PvRBP alone. I, input. U, unbound. E, eluate. (B) Measured FRET 
fluorescence intensity of the interaction between PvRBP2b-Dylight488 and TfR1-
Dylight594 incubated at 1:1 molar concentration (no inh) either in the presence of 
unlabeled proteins (PfRh4, PvRBP2b, TfR1 and binary complex TfR1-Tf) or SDS as a 
denaturant. The fluorescence intensity (FI) of DyLight-488 (donor) was measured with a 
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485/14-nm excitation filter and a 535/25-nm emission filter and DyLight-594 was 
measured with a 590/20-nm excitation filter and 615/9-nm emission filter. (C) The 
interaction between PvRBP2b and TfR1-Tf binary complex is similar in the presence of 
iron-depleted (TfAPO) and iron-loaded (TfHOLO) form of human transferrin. The exclusion 
volume (V0) of the columns and the elution volumes of selected marker proteins are 
indicated with black arrowheads. Lower part: Coomassie-Blue stained SDS-PAGE gels 
of the fractions obtained from SEC. PvRBP2b161-1454 was used in panels A, B and C. (D) 
PvRBP2a does not interact with the TfR1-Tf binary complex as analyzed by SEC. 
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Figure S3. Detailed analyses of PvRBP2b structure. (A) Analysis of the packing of the 
molecules in the crystal. Left panel: General view of the crystal. Black lines represent the 
edges of the unit cell. Middle panel: Two molecules, MolA and MolB, present in the 
asymmetric unit can be seen in head-to-tail orientation. Both molecules consist of 301 
residues spanning 169 to 470 amino acids of PvRBP2b and additionally include a di-
peptide Gly-Ser fragment which was introduced as a cloning artifact. The buried interface 
area between two molecules present in the ASU is around 719 Å2 as calculated using 
PISA server. Right panel: the most important crystal contact between molecules A and B 
from the neighboring asymmetric units buries around 915 Å2 of the interface area. 
Molecules A and B are colored in green and cyan, respectively and shown as ribbon and 
surface representation. (B) Representative electron density around the disulphide bond 
formed between Cys312 and Cys316. The short beta-sheet formed between strands β3 
and β4 is also visible. The 2Fobs-Fcalc map is contoured at 2σ and shown as blue mesh. 
Protein is shown in ball and stick representation with carbon shown in green, nitrogen in 
blue, oxygen in red and sulfur in yellow. The hydrogen bond network between strands β3 
and β4 is shown as yellow dashed line. (C) Superimposition of the two molecules from 
the asymmetric unit. Molecules are shown as ribbons colored with the colors 
corresponding to the RMSD between two molecules in the range from 0.01 to 0.46 Å. 
Dark blue shows good alignment, higher deviations are in orange/yellow/red. Residues 
not used for alignment are colored white. (D) Analysis of B-factors. The most flexible 
regions include a loop interconnecting helices α1 with α2a and helices α4 with α5. 
Molecule is shown as cartoon putty representation. The width of the structure as well as 
the colors changing from blue to red are proportional to the average residue temperature 
factor changing in the range from 18.45 to 98.65 Å2. The protein regions with high 
temperature factors are shown as wide orange/red tubes. 
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Figure S4. Sequence alignment of the crystallized fragments of PvRBP2a and 
PvRBP2b. The sequence alignment was generated using Clustal Omega and manually 
refined. The figure was prepared using ESPript3 (http://espript.ibcp.fr/ESPript/ESPript). 
The secondary structures of PvRBP2a and PvRBP2b are shown above and below the 
sequences, respectively. Identical residues are highlighted in red boxes whereas similar 
residues are colored red in white boxes. The positions of conserved cysteine residues are 
marked with green stars and labeled with corresponding numbers. 
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Figure S5. Small angle X-ray scattering analysis of PvRBP2b169-470. (A) Scattering 
intensity profile for PvRBP2b169-470. The background-subtracted SAXS data are shown as 
black circles representing natural logarithm of mean intensity lnI(q) as a function of 
momentum transfer q in Å-1 (a.u. - arbitrary unit). The theoretical scattering profile (red 
line) calculated from the crystal structure was fitted to the experimental scattering data of 
PvRBP2b169-470 using CRYSOL with c value of 0.35. (B) Two orthogonal views of ab 
initio bead models of PvRBP2b169-470 represented as grey spheres, superimposed with the 
crystal structure of the same construct. (C) Guinier plot for qRg ≤ 1.3. The radius of 
gyration and initial scattering intensity I(0) were approximated using the Guinier 
equation with PRIMUS. The values are presented in Table S2. (D) Residuals for the 
Guinier plot. (E) Pair-wise inter-atomic distance distribution function, P(r). The Rg and 
maximum particle dimension Dmax calculated from the P(r) analysis are as indicated in 
Table S2. (F) Kratky plot analysis of the SAXS data. 
22 
Figure S6. Small angle X-ray scattering analysis of different constructs of PvRBP2b. 
(A) Arbitrarily offset scattering intensity profiles from the apex of in-line size-exclusion
column elution peaks for PvRBP2b169-652 (top), PvRBP2b474-969 (middle) and
PvRBP2b161-969 (bottom). The SAXS data are shown as black circles. Solid red line
represents a calculated scattering pattern of an average ab initio model. The c value
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indicating the fit of the average model to the experimental data was calculated using 
CRYSOL. (B) Two orthogonal views of ab initio bead models of PvRBP2b represented 
as grey spheres, superimposed with crystal structure of P. vivax PvRBP2b169-470: 
PvRBP2b169-652 (top), PvRBP2b474-969 (middle) and PvRBP2b161-969 (bottom). (C) Guinier 
plots for qRg ≤ 1.3. (D) Residuals for the Guinier plot. (E) Pair-wise inter-atomic distance 
distribution function, P(r). (F) Kratky plot analysis of the SAXS data. 
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Figure S7. Twenty ab initio models generated using program DAMMIF based on 
SAXS data collected for each PvRBP2b fragment. (A) PvRBP2b169-470. (B) 
PvRBP2b169-652. (C) PvRBP2b161-969. (D) PvRBP2b474-969. * indicates the models that 
were not included in averaging due to their normalized spatial discrepancy parameter 
NSD being higher than the mean value plus two times standard deviation. 
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Figure S8.  Circular dichroism spectra of recombinant PvRBP2b variants, Tf and 
TfR1. Circular dichroism spectra of recombinant PvRBP2b variants (A) and Tf, TfR1 
and TfR1 DG217 mutant (B). The signal is presented as mean residue molar ellipticity 
(θ). (C) SDS-PAGE gel of purified PvRBP2b recombinant proteins. Two micrograms of 
each protein were loaded onto a 4-12% NuPAGE gradient gel under reducing conditions 
and stained with Coomassie Brilliant Blue. Molecular mass marker (M) indicated in kDa. 
(D) Secondary structures prediction for PvRBP2b (residues 1-1,500) obtained using JNet. 
JNetPRED represents the consensus prediction with helices marked as red tubes and 
sheets as green arrows. JNetCONF shows the confidence estimate for the prediction. 
High values mean high confidence. 
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Figure S9.  Sedimentation velocity analysis of transferrin receptor-transferrin 
complex binding to PvRBP2b161-969. Radial scans from the analytical ultracentrifuge are 
shown as circles, and the best fit to a continuous sedimentation coefficient distribution 
shown as solid lines. 
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Figure S10. Identification of TFRC mutations introduced by CRISPR/Cas9. TIDE 
analysis of the two TFRC clones shows that ΔTFRC-1 is homozygous for a -3 bp 
deletion (A) while ΔTFRC-2 is a heterozygote, containing both a -3 bp and a -11 bp 
deletion (B). (C) The sgRNA target site (salmon) is shown along with the PAM 
sequences and the Cas9-cut site. The exact size and location of the -3 bp and -11 bp 
deletions are shown and have been identified from Sanger sequencing data. The -3 bp 
deletion results in the in-frame loss of Gly217, while the -11 bp deletion results in a 
premature stop codon. (D) The position of residue Gly217 (magenta spheres) mapped on 
the crystal structure of TfR1 ectodomain bound to MACV GP1 (PDB ID: 3KAS). The 
Gly217 mutation is localized in the loop lying in the close vicinity of helix αII-2 and 
sheet βII-2 that are the main interaction sites with MACV GP1. The particular domains in 
one monomer of TfR1 are colored with protease-like domain shown in red, helical 
domain in yellow and the apical domain in green. The other molecule of TfR1 is shown 
in cyan. MACV GP1 is shown in blue. N-linked glycan moieties decorating the surface of 
both proteins are shown as sticks. (E) Light microscopy images of parasite invasion. 
Invasion of P. vivax into JK-1 WT (top left) and TfR1 mut cells (top right) and invasion 
of P. falciparum 3D7 into JK-1 WT (bottom left) and TfR1 mut cells (bottom right). 
Parasitized cells are indicated by red arrows. Insets show close-up views of infected cells. 
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Figure S11. Expression of TfR1 on the surface of jkRBC and TfR1 mutant cells as 
measured by flow cytometry using nine anti-TfR1 monoclonal antibodies as 
indicated. The antibody control reflects the staining of the secondary antibody alone. 
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Figure S12. Detection of recombinant PvRBP2b fragments by ELISA. (A) ELISA 
plates were coated with equimolar concentrations of each recombinant fragment and 
detection with anti-PvRBP2b rabbit polyclonal antibody (left) and anti-PfRh4 mAb 10C9 
(right) are shown. Representative plot of n=3 is shown and error bars represent range of 
duplicate measurement per experiment. (B) ELISA plates were coated with equimolar 
concentrations of each recombinant fragment (top label) and detection with primary 
monoclonal antibodies against PvRBP1a (4E3), PvRBP1b (4G4), PvRBP2a (3A11), 
PvRBP2b (3E9, 6H1, 8G7 and 10B12), PvRBP2cNB (6H2) and PvRBP2-P2 (9E3) are 
shown. Representative plot of n=2 is shown and error bars represent range of duplicate 
measurement per experiment. (C) Interaction between anti-PvRBP2b monoclonal 
antibodies and PvRBP2b measured by SPR. PvRBP2b161-1454 was immobilized via 
standard amine coupling onto carboxymethyldextran sensorchips and 3E9, 6H1 and 
10B12 mAbs were flown over the surfaces at the concentrations 40, 52 and 40 nM, 
respectively. The binding curves were fit to a bivalent (2:1) interaction model. 
Sensorgrams of the interaction are displayed in yellow and the fitted curves are displayed 
as black dashes; RU - resonance units.  
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Table S1. Crystallographic data collection and refinement statistics. 
 PvRBP2b169-470 
Data collection statistics  
   Space group P 1 21 1 
   Unit-cell dimensions  
      a, b, c (Å) 59.50, 124.20, 65.31 
      a, b, g (°) 90.00, 97.75, 90.00 
   Wavelength (Å) 0.95370 
   Resolution (Å) 34.87 - 1.71 (1.74 - 1.71) 
   Number of unique reflections 100,494 (4,872) 
   Rmergea 0.11 (1.71) 
   Rpimb 0.04 (0.66) 
   <I/sI> 10.0 (1.2) 
   Completeness (%) 99.4 (98.8) 
   Multiplicity 7.4 (7.5) 
   CC1/2c 0.996 (0.551) 
   Wilson B-factor (Å2) 25.1 
Refinement statistics  
   Resolution (Å) 34.17 - 1.71 (1.80 - 1.71) 
   Unique reflections 100,440 
   Rworkd 0.168 (0.273) 
   Rfreed 0.188 (0.305) 
   Number of atoms 5947 
      Protein 5100 
      Ligand 23 
      Solvent 824 
   Average B-factors (Å2) 35.5 
      Protein 33.8 
      Ligands 54.1 
      Solvent 45.3 
   R.m.s. deviations  
      Bond lengths (Å) 0.014 
      Bond angles (°) 1.32 
   Ramachandran plot (%)  
      Most favored 98.2 
      Allowed 1.8 
      Outlier 0 
Statistics for the highest-resolution shell are shown in parentheses. 
Data were collected on a single crystal. 
aRmerge = ΣhklΣi│Ii(hkl) - <I(hkl)>│/ Σhkl Σi Ii(hkl) (80). 
bRpim = Σhkl {1/[N(hkl) - 1]}1/2 x Σj│Ii(hkl) - <I(hkl)>│/ Σhkl Σj Ii(hkl) (81). 
c CC1/2 = Pearson correlation coefficient between independently merged halves of the data 
set (82). 
dRwork = Σhkl│Fo(hkl) - Fc(hkl)│/ Σhkl Fo(hkl). Rfree was calculated for a test set of 
reflections omitted from the refinement. 
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Table S2. SAXS data collection and analysis statistics. 
 
Data-collection parameters  
Instrument Australian Synchrotron SAXS/WAXS beamline 
Beam geometry  
Wavelength (Å)  
Exposure time (s) 
Protein concentration  
Temperature (°C) 
120 µm point source 
1.033 
2 
between 3.0 and 8.0 mg/ml via in-line gel filtration chromatography  
16 
Software employed  
Primary data reduction 
Data processing 
Ab initio modelling 
Rigid-body modelling 
3D graphics representations 
ScatterBrain (Australian Synchrotron) 
PRIMUS, GNOM 
DAMMIF, DAMSEL, DAMSUP, DAMAVER, DAMFILT 
COLORES 
MacPyMOL 
 
 
Structural parameters PvRBP2b169-470 PvRBP2b169-652 PvRBP2b474-969 PvRBP2b161-969 
I(0) (cm-1) from P(r) 0.01316 ± 0.00012 0.01411 ± 0.00012 0.01143 ± 0.00006 0.01231 ± 0.00007 
Rg (Å) from P(r) 25.96 ± 0.32 43.79 ± 0.42 63.99 ± 0.40 82.03 ± 0.49 
Dmax (Å) 88 ± 2 140 ± 3 213 ± 5 265 ± 7 
I(0) (cm-1) from Guinier 0.013 ± 0.001 0.014 ± 0.001 0.011 ± 0.001 0.012 ± 0.001 
Rg (Å) from Guinier 25.40 ± 0.52 41.3 ± 0.80 60.60 ± 0.61 81.40 ± 1.00 
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Table S3. List of the oligonucleotides used in this study to create different variants 
of PvRBP2b protein. 
 
Oligonucleotide Construct Vector Sequence 
    
JG125 
PvRBP2b169-470 pPROEX HTb 
AAC CTG TAT TTT CAG GGC GCC ATG GGA TCC 
ACC AAT ACC ACC GAT AAC ATC GAT 
JG126 GCC AAG CTT GGT ACC GCA TGC CTC GAG TCA GCT AAT ACG TTC TTC CAG ATG ACC 
    
JG125 
PvRBP2b169-652 pPROEX HTb 
AAC CTG TAT TTT CAG GGC GCC ATG GGA TCC 
ACC AAT ACC ACC GAT AAC ATC GAT 
JG213 GCC AAG CTT GGT ACC GCA TGC CTC GAG TCA ATA TTC GAT AAT TTT GTT AAT ATC TTC TTT 
    
JG125 
PvRBP2b169-813 pPROEX HTb 
AAC CTG TAT TTT CAG GGC GCC ATG GGA TCC 
ACC AAT ACC ACC GAT AAC ATC GAT 
JG215 GCC AAG CTT GGT ACC GCA TGC CTC GAG TCA GCT GGA CTT CAG GGC ATT ATA TTC TTT GGT 
    
JG51 
PvRBP2b161-969 pET-32a(+) 
TAA TAC GAC TCA CTA TAG GGG 
JG159 TTG TTC AAC GCT CTG CTG ATT GCT TCA GCT ACG TTT CAT GGC AAT ATT CAC TTT 
    
JG160 
PvRBP2b474-969 pET-32a(+) 
CTG TAT TTT CAG GGC GCC ATG GGA TCC GAT 
AGC GAG TAT TTT ATC ACC GAA AGC 
JG159 TTG TTC AAC GCT CTG CTG ATT GCT TCA GCT ACG TTT CAT GGC AAT ATT CAC TTT 
    
JG160 
PvRBP2b474-1454 pET-32a(+) 
CTG TAT TTT CAG GGC GCC ATG GGA TCC GAT 
AGC GAG TAT TTT ATC ACC GAA AGC 
JG161 GCT TTC GGT GAT AAA ATA CTC GCT ATC GGA TCC CAT GGC GCC CTG AAA ATA CAG 
    
JG71 
PvRBP2b161-1454 PET-32a(+) 
GGT TCT GAA AAC CTG TAT TTT CAG GGC GCC 
AAC ATC GAT TAC TTC GAT ATT TCC 
JG73 GCT TTG TTA GCA GCC GGA TCT CAG TCA TGC CTG TTT TTC AAA GTT TTC GG 
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Table S4. Molecular weights and absorption coefficients for the proteins used in this 
study. 
 
Protein name MW (kDa) A280 0.1% e280 (M-1cm-1) Source 
PvRBP2b169-470 36.46 0.868 31,540 ExPASy 
PvRBP2b169-652 57.88 0.880 50,910 ExPASy 
PvRBP2b169-813 76.89 0.701 53,890 ExPASy 
PvRBP2b161-969 96.68 0.619 59,850 ExPASy 
PvRBP2b161-1454 152.9 0.545 83,355 ExPASy 
PvRBP2b474-969 58.73 0.482 28,310 ExPASy 
PvRBP2b474-1454 114.9 0.451 51,815 ExPASy 
Tf 79.60a 1.305 103,900 (45) 
(TfR1)2 156.6b 1.198 187,580 (43) 
(TfR1-Tf)2 315.8c 1.252 395,380 (43, 45) 
 
 
aTheoretical MW = 77.06 kDa. The value in the table was obtained using mass 
spectrometry and reflects glycosylation of the protein. 
bTheoretical MWmonomer = 73.82 kDa. The value in the table was obtained using mass 
spectrometry and reflects glycosylation of the protein. The protein forms a homodimer. 
cThe proteins form a 2:2 complex. 
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Table S5. Analytical size exclusion chromatography. 
(A) Molecular weights of high- and mid-mass molecular mass markers used for the 
calibration of the analytical size exclusion column. (B) Experimental molecular weights 
for the particular proteins. 
 
A 
 
Protein name MWa (Da) log10 MW Veb (ml) Kavc 
aprotinin 6,500 3.8129 19.51 0.7334 
ribonuclease 13,700 4.1367 17.82 0.6221 
carbonic anhydrase 29,000 4.4624 16.41 0.5293 
ovoalbumin 44,000 4.6435 15.06 0.4404 
conalbumin 75,000 4.8751 14.24 0.3864 
aldolase 158,000 5.1987 12.81 0.2923 
ferritin 440,000 5.6435 10.55 0.1435 
thyroglobulin 669,000 5.8254 9.24 0.0573 
 
B 
 
Protein name Vea (ml) Kavb 
Calculated 
MW (kDa) 
Theoretical 
MW (kDa) 
PvRBP2b169-470 16.21 0.5161 29.67 36.46 
PvRBP2b161-969 11.36 0.1968 280.0 96.68 
PvRBP2b474-969 12.27 0.2567 183.8 58.73 
PvRBP2b161-1454 9.69 0.0869 606.6 152.9 
PvRBP2b474-1454 10.04 0.1099 515.9 114.9 
     
Tf 13.76 0.3548 92.21 79.60 
(TfR1)2 13.49 0.3371 104.5 156.6 
(TfR1-Tf)2 11.21 0.1870 300.2 315.8 
     
(PvRBP2b161-969-TfR1-Tf)2 10.10 0.1139 501.8 509.2 
(PvRBP2b161-1454-TfR1-Tf)2 9.11 0.0487 793.4 621.6 
 
aMW – molecular weight 
bVe – elution volume 
cKav = (Ve – V0)/(Vc –V0), partition coefficient, where V0 = 8.37 ml, column void volume 
obtained using a sample of blue dextran 2000 and Vc = 23.56 ml, geometric column 
volume. Kav = -0.3275 x log10MW + 1.9808, R2 = 0.9971. 
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Table S6. SPR measurements of mAbs-PvRBP2b interactions. 
mAb ka1 (M-1s-1) 
kd1 
(s-1) 
KD1 
(M) 
ka2 
([signal]-1s-1) 
kd2 
(s-1) 
KD2 
(M) 
c2 
([signal]2) 
Rmax 
(calculated) 
3E9 7.1 x 104 3.7 x 10-4 5.2 x 10-9 5.8 x 10-2 7.2 x 100 1.2 x 102 1.6 541 
6H1 1.6 x 105 4.9 x 10-4 3.0 x 10-9 8.1 x 10-3 1.3 x 102 1.6 x 100 5.3 848 
10B12 5.5 x 104 4.9 x 10-7 8.8 x 10-12 2.3 x 10-1 5.4 x 10-3 2.4 x 10-2 36 898 
 
The binding curves obtained from the experiment were fit to a bivalent (2:1) interaction 
model to estimate affinity constants for the bivalent interaction. 
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Additional Database  
Dataset S1. Quantitative surface proteomics analysis comparing WT jkRBCs and 
TfR1 mut1 and TfR1 mut2 jkRBC lines. For each protein, the following data fields are 
shown: UniProt ID; Gene Symbol; Description, Gene Ontology Cellular Compartment-
term classification: M – membrane, PM – plasma membrane, IPM – integral to plasma 
membrane, CS – cell surface, XC – extracellular, Nuc – nuclear, ShG – short GO) (52, 
83); number of identified peptides, fold change (FC) of average jkRBC signal:noise (S:N) 
compared to the average TfR1 Mut-1/2 (S:N); normalized S:N for each protein. The 
“No_Filter” worksheet includes all identified proteins and the 
“PM_CS_XC_ShG_2_peptides” worksheet shows the subset of plasma membrane 
proteins. 
 
